Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, European Journal of Pharmacology, 1-3(672), p. 1-8, 2011

DOI: 10.1016/j.ejphar.2011.08.047

Links

Tools

Export citation

Search in Google Scholar

Pathogenesis and pharmacotherapy of Hidradenitis suppurativa

Journal article published in 2011 by Maiwand Nazary, H. H. van der Zee, E. P. Prens ORCID, Gert Folkerts, Jurr Boer
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The focus of this review is to discuss the pathogenesis and the pharmacotherapy of Hidradenitis suppurativa (HS). HS is a distressing chronic skin disorder characterized by abscesses, boils, fistulas and scarring, generally affecting the groins, anogenital area and axillae. It is a common disease with an estimated prevalence of 1%. The etiology is unknown. HS was thought to be a disease of the apocrine sweat glands, but histological findings indicate that HS is a disease arising from the hair follicles. Several pathogenic factors seem important including genetic predisposition, smoking, obesity and an aberrant immune response to commensal flora. The management of HS is tremendously challenging because effective therapies are lacking. Nevertheless, HS has been treated with topical and systemic antibiotics, retinoids and immunosuppressive drugs such as anti-TNF-α biologics with partial success. In this review we will also discuss a potential new therapy for HS with the anti-psoriases agent acitretin.